Join Sensei Biotherapeutics for a virtual key opinion leader (KOL) event featuring company leadership and Kyriakos Papadopoulos, MD (Co-Director of Clinical Research at START, San Antonio), who will discuss the unmet need and current treatment landscape for immunotherapy-resistant solid tumors.

The event will provide an update on the Company’s plans for Phase 2 studies and data from the full Phase 1/2 dose expansion cohort, including from the ESMO oral presentation on Friday, October 17th. Solnerstotug (formerly SNS-101), is a conditionally active monoclonal antibody targeting VISTA (V-domain Ig suppressor of T cell activation) in PD-(L)1 resistant tumors.

A live question and answer session will follow the formal presentations.